华神科技：第十三届监事会第十六次会议决议公告

Group 1 - The company announced the approval of the performance commitment completion for Tibet Kangyu Pharmaceutical Co., Ltd. for the year 2024 [2] - The company plans to publicly transfer 51% equity stake in Tibet Kangyu Pharmaceutical [2]